How big is the Non-Alcoholic Fatty Liver Disease Market?

The Non-Alcoholic Fatty Liver Disease Market size is expected to reach USD 21.36 billion in 2024 and grow at a CAGR of 9.56% to reach USD 33.72 billion by 2029. Read More

What is the current Non-Alcoholic Fatty Liver Disease Market size?

In 2024, the Non-Alcoholic Fatty Liver Disease Market size is expected to reach USD 21.36 billion. Read More

Who are the key players in Non-Alcoholic Fatty Liver Disease Market?

Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Novo Nordisk A/S, Gilead Sciences, Inc. and AbbVie, Inc. are the major companies operating in the Non-Alcoholic Fatty Liver Disease Market. Read More

Which is the fastest growing region in Non-Alcoholic Fatty Liver Disease Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Non-Alcoholic Fatty Liver Disease Market?

In 2024, the North America accounts for the largest market share in Non-Alcoholic Fatty Liver Disease Market. Read More

What years does this Non-Alcoholic Fatty Liver Disease Market cover, and what was the market size in 2023?

In 2023, the Non-Alcoholic Fatty Liver Disease Market size was estimated at USD 19.32 billion. The report covers the Non-Alcoholic Fatty Liver Disease Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Non-Alcoholic Fatty Liver Disease Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Non-Alcoholic Fatty Liver Disease (NAFLD) Market Share

Statistics for the 2023 & 2024 Non-Alcoholic Fatty Liver Disease (NAFLD) market share, created by Mordor Intelligence™ Industry Reports. Non-Alcoholic Fatty Liver Disease (NAFLD) share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Non-Alcoholic Fatty Liver Disease (NAFLD) Industry

The non-alcoholic fatty liver disease market is consolidated in terms of ongoing research and development and pharmaceutical pipeline development. The pharmaceutical landscape for NAFLD is dominated by companies that are heavily investing in developing therapeutics for the condition. Some of the key players are Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Gilead Sciences Inc., AbbVie Inc., and Novo Nordisk AS.